Target-independent variable region mediated effects on antibody clearance can be FcRn independent

mAbs

Volumn 8, Issue 7, 2016, Pages 1269-1275

  Kelly, Ryan L ^a   Yu, Yao ^b   Sun, Tingwan ^b   Caffry, Isabelle ^b   Lynaugh, Heather ^b   Brown, Michael ^b   Jain, Tushar ^c   Xu, Yingda ^a   Wittrup, K Dane ^a  

^a Massachusetts Institute of Technology   (United States)

^b Protein Analytics Adimab   (United States)

^c NONE   (United States)

Author keywords

Clearance; cross interaction; developability; monoclonal antibody; neonatal Fc receptor (FcRn); nonspecificity; PK; polyreactivity; self interaction

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; FC RECEPTOR; MONOCLONAL ANTIBODY; USTEKINUMAB; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1;

ANTIBODY PRODUCTION; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; INTERFEROMETRY; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PHENOTYPE; PLASMA HALF LIFE; PROTEIN INTERACTION; SIZE EXCLUSION CHROMATOGRAPHY; ANIMAL; ANTIBODY AFFINITY; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MICE; RECEPTORS, FC; USTEKINUMAB;

EID: 84987624697     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1208330     Document Type: Article

References (46)

1. J.Zalevsky, A.K.Chamberlain, H.M.Horton, S.Karki, I.W.L.Leung, T.J.Sproule, G.A.Lazar, D.C.Roopenian, J.R.Desjarlais. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol [Internet] 2010 [cited 2014Dec30]; 28:157-9. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2855492&tool=pmcentrez&rendertype=abstract; PMID:20081867; http://dx.doi.org/10.1038/nbt.1601
2. R.P.Lyon, T.D.Bovee, S.O.Doronina, P.J.Burke, J.H.Hunter, H.D.Neff-LaFord, M.Jonas, M.E.Anderson, J.R.Setter, P.D.Senter. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol [Internet] 2015; 33:733-5. Available from:http://www.nature.com/doifinder/10.1038/nbt.3212; PMID:26076429; http://dx.doi.org/10.1038/nbt.3212
3. M.A.Tabrizi, C.L.Tseng, L.K.Roskos. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11:81-8; PMID:16478695; http://dx.doi.org/10.1016/S1359-6446(05)03638-X
4. R.Junghans, C.Anderson. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci [Internet] 1996 [cited 2015Jan29]; 93:5512-6. Available from:http://www.pnas.org/content/93/11/5512.short; PMID:8643606; http://dx.doi.org/10.1073/pnas.93.11.5512
5. B.Gurbaxani, M.Dostalek, I.Gardner. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?. Mol Immunol [Internet] 2013 [cited 2014Aug31]; 56:660-74. Available from:http://dx.doi.org/10.1016/j.molimm.2013.05.008; PMID:23917469; http://dx.doi.org/10.1016/j.molimm.2013.05.008
6. D.C.Roopenian, S.Akilesh. FcRn:the neonatal Fc receptor comes of age. Nat Rev Immunol [Internet] 2007; 7:715-25. Available from:http://www.nature.com/doifinder/10.1038/nri2155; PMID:17703228; http://dx.doi.org/10.1038/nri2155
7. W.P.Burmeister, L.N.Gastinel, N.E.Simister, M.L.Blum, P.J.Bjorkman. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 1994; 372:336-43; PMID:7969491; http://dx.doi.org/10.1038/372336a0
8. W.P.Burmeister, A.H.Huber, P.J.Bjorkman. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994; 372:379-83; PMID:7969498; http://dx.doi.org/10.1038/372379a0
9. W.F.Dall'Acqua, P.A.Kiener, H.Wu. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem [Internet] 2006 [cited 2015Jan15]; 281:23514-24. Available from:http://www.jbc.org/cgi/doi/10.1074/jbc.M604292200; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
10. P.R.Hinton, M.G.Johlfs, J.M.Xiong, K.Hanestad, K.C.Ong, C.Bullock, S.Keller, M.T.Tang, J.Y.Tso, M.Vásquez, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem [Internet] 2004 [cited 2015Jan29]; 279:6213-6. Available from:http://www.ncbi.nlm.nih.gov/pubmed/14699147; PMID:14699147; http://dx.doi.org/10.1074/jbc.C300470200
11. S.B.Petkova, S.Akilesh, T.J.Sproule, G.J.Christianson, H.Al Khabbaz, A.C.Brown, L.G.Presta, Y.G.Meng, D.C.Roopenian. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model:Potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-69; PMID:17077181; http://dx.doi.org/10.1093/intimm/dxl110
12. A.Datta-Mannan, J.Lu, D.R.Witcher, D.Leung, Y.Tang, V.J.Wroblewski. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs [Internet] 2015; 7:1-10. Available from:http://www.tandfonline.com/doi/full/10.1080/19420862.2015.1075109; PMID:25484055; http://dx.doi.org/10.1080/19420862.2015.1075109
13. Y.A.Yeung, M.K.Leabman, J.S.Marvin, J.Qiu, C.W.Adams, S.Lien, M.A.Starovasnik, H.B.Lowman. Engineering human IgG1 affinity to human neonatal Fc receptor:impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID:19494290; http://dx.doi.org/10.4049/jimmunol.0804182
14. Y.N.Abdiche, Y.A.Yeung, J.Chaparro-Riggers, I.Barman, P.Strop, S.M.Chin, A.Pham, G.Bolton, D.McDonough, K.Lindquist, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs [Internet] 2015; 7:331-43. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25658443; PMID:25658443; http://dx.doi.org/10.1080/19420862.2015.1008353
15. T.Igawa, H.Tsunoda, T.Tachibana, A.Maeda, F.Mimoto, C.Moriyama, M.Nanami, Y.Sekimori, Y.Nabuchi, Y.Aso, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel [Internet] 2010 [cited 2014Aug29]; 23:385-92. Available from:http://www.ncbi.nlm.nih.gov/pubmed/20159773; PMID:20159773; http://dx.doi.org/10.1093/protein/gzq009
16. B.Li, D.Tesar, C.A.Boswell, H.S.Cahaya, A.Wong, J.Zhang, Y.G.Meng, C.Eigenbrot, H.Pantua, J.Diao, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs [Internet] 2014; 6:1255-64. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25517310; PMID:25517310; http://dx.doi.org/10.4161/mabs.29809
17. A.Schoch, H.Kettenberger, O.Mundigl, G.Winter, J.Engert, J.Heinrich, T.Emrich. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci [Internet] 2015; 112:5997-6002. Available from:http://www.pnas.org/lookup/doi/10.1073/pnas.1408766112; PMID:25918417; http://dx.doi.org/10.1073/pnas.1408766112
18. A.Datta-Mannan, A.Thangaraju, D.Leung, Y.Tang, D.R.Witcher, J.Lu, V.J.Wroblewski, R.Derrick, J.Lu, V.J.Wroblewski. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. MAbs [Internet] 2015; 7:483-93. Available from:http://www.tandfonline.com/doi/full/10.1080/19420862.2015.1016696; PMID:25695748; http://dx.doi.org/10.1080/19420862.2015.1016696
19. T.Suzuki, A.Ishii-Watabe, M.Tada, T.Kobayashi, T.Kanayasu-Toyoda, T.Kawanishi, T.Yamaguchi. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1:a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol [Internet] 2010 [cited 2014Dec1]; 184:1968-76. Available from:http://www.ncbi.nlm.nih.gov/pubmed/20083659; PMID:20083659; http://dx.doi.org/10.4049/jimmunol.0903296
20. W.Wang, P.Lu, Y.Fang, L.Hamuro, T.Pittman, B.Carr, J.Hochman, T.Prueksaritanont, W.E.T.Al. Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences. Drug Metab Dispos 2011; 39:1469-77; PMID:21610128; http://dx.doi.org/10.1124/dmd.111.039453
21. M.Liu, G.Yang, K.Wiehe, N.I.Nicely, N.A.Vandergrift, W.Rountree, M.Bonsignori, S.M.Alam, J.Gao, B.F.Haynes, et al. Polyreactivity and Autoreactivity among HIV-1 Antibodies. J Virol [Internet] 2015; 89:784-98. Available from:http://jvi.asm.org/lookup/doi/10.1128/JVI.02378-14; PMID:25355869; http://dx.doi.org/10.1128/JVI.02378-14
22. G.Sigounas, N.Harindranath, G.Donadel, A.L.Notkins. Half-life of polyreactive antibodies. J Clin Immunol [Internet] 1994; 14:134-40. Available from:http://www.ncbi.nlm.nih.gov/pubmed/8195315; PMID:8195315; http://dx.doi.org/10.1007/BF01541346
23. S.A.Sievers, L.Scharf, A.P.West, P.J.Bjorkman. Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS [Internet] 2015; 10:151-9. Available from:http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01222929-900000000-99538; PMID:25760931; http://dx.doi.org/10.1097/COH.0000000000000148
24. I.Hotzel, F.-P.Theil, L.J.Bernstein, S.Prabhu, R.Deng, L.Quintana, J.Lutman, R.Sibia, P.Chan, D.Bumbaca, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs [Internet] 2012 [cited 2013Jan24]; 4:753-60. Available from:http://migrate.landesbioscience.com/journals/mabs/article/22189/?show_full_text=true; PMID:23778268; http://dx.doi.org/10.4161/mabs.22189
25. R.L.Kelly, T.Sun, T.Jain, I.Caffry, Y.Yu, Y.Cao, H.Lynaugh, M.Brown, M.Vásquez, K.D.Wittrup, et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs [Internet] 2015; 7:00-00. Available from:http://www.tandfonline.com/doi/full/10.1080/19420862.2015.1043503; PMID:NOT_FOUND; http://dx.doi.org/10.1080/19420862.2015.1043503
26. A.Datta-Mannan, V.J.Wroblewski. Application of FcRn Binding Assays to Guide mAb Development. Drug Metab Dispos [Internet] 2014; 42:1867-72. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25024401; PMID:25024401; http://dx.doi.org/; http://dx.doi.org/10.1124/dmd.114.059089
27. A.Bajardi-Taccioli, A.Blum, C.Xu, Z.Sosic, S.Bergelson, M.Feschenko. Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics. Mol Immunol [Internet] 2015; 67(2 Pt B):616-24; Available from:http://linkinghub.elsevier.com/retrieve/pii/S0161589015300067; PMID:26254986; http://dx.doi.org/10.1016/j.molimm.2015.06.031
28. M.Gandhi, E.Alwawi, K.B.Gordon. Anti-p40 Antibodies Ustekinumab and Briakinumab:Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis. Semin Cutan Med Surg 2010; 29:48-52; PMID:20430307; http://dx.doi.org/10.1016/j.sder.2010.02.001
29. J.Giles-Komar, D.M.Knight, D.Peritt, B.Scallon, D.Shealy. Anti-IL-12 antibodies and compositions thereof. 2005.
30. WHO. International Nonproprietary Names for Pharmaceutical Substances (INN):Recommended International Nonproprietary Names List 63. WHO Drug Inf 2010; 24:41-80.
31. S.A.Jacobs, S.-J.Wu, Y.Feng, D.Bethea, K.T.O'Neil. Cross-interaction chromatography:a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res [Internet] 2010 [cited 2012Dec31]; 27:65-71. Available from:http://www.ncbi.nlm.nih.gov/pubmed/19911257; PMID:19911257; http://dx.doi.org/10.1007/s11095-009-0007-z
32. Y.Xu, W.Roach, T.Sun, T.Jain, B.Prinz, T.-Y.Yu, J.Torrey, J.Thomas, P.Bobrowicz, M.Vásquez, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system:a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel [Internet] 2013 [cited 2014Jan21]; 26:663-70. Available from:http://www.ncbi.nlm.nih.gov/pubmed/24046438; PMID:24046438; http://dx.doi.org/10.1093/protein/gzt047
33. S.V.Sule, C.D.Dickinson, J.Lu, C.-K.Chow, P.M.Tessier. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm [Internet] 2013; 10:1322-31. Available from:http://www.ncbi.nlm.nih.gov/pubmed/23383873; PMID:23383873; http://dx.doi.org/10.1021/mp300524x
34. J.Jayaraman, J.Wu, M.C.Brunelle, A.M.M.Cruz, D.S.Goldberg, B.Lobo, A.Shah, P.M.Tessier. Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy. Biotechnol Bioeng [Internet] 2014 [cited 2014Aug12]; 111:1513-20. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25367343; PMID:25097914; http://dx.doi.org/10.1002/bit.25221
35. L.J.Fan. PDB ID:4NYL. Crystal structure of adalimumab FAB fragment. To be Publ [Internet] [cited 2016Mar25]; Available from:http://www.rcsb.org/pdb/explore/explore.do?structureId=4nyl; http://dx.doi.org/10.2210/pdb4nyl/pdb
36. J.Luo, S.J.Wu, E.R.Lacy, Y.Orlovsky, A.Baker, A.Teplyakov, G.Obmolova, G.A.Heavner, H.T.Richter, J.Benson. Structural Basis for the Dual Recognition of IL-12 and IL-23 by Ustekinumab. J Mol Biol [Internet] 2010; 402:797-812. Available from:http://dx.doi.org/10.1016/j.jmb.2010.07.046; PMID:20691190; http://dx.doi.org/10.1016/j.jmb.2010.07.046
37. T.Schlothauer, P.Rueger, J.O.Stracke, H.Hertenberger, F.Fingas, L.Kling, T.Emrich, G.Drabner, S.Seeber, J.Auer, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs 2013; 5:576-86; PMID:23765230; http://dx.doi.org/10.4161/mabs.24981
38. S.Birtalan, Y.Zhang, F.A.Fellouse, L.Shao, G.Schaefer, S.S.Sidhu. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J Mol Biol [Internet] 2008 [cited 2013Feb12]; 377:1518-28. Available from:http://www.ncbi.nlm.nih.gov/pubmed/18336836; PMID:18336836; http://dx.doi.org/10.1016/j.jmb.2008.01.093
39. C.A.Boswell, D.B.Tesar, K.Mukhyala, F.P.Theil, P.J.Fielder, L.A.Khawli. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010; 21:2153-63; PMID:21053952; http://dx.doi.org/10.1021/bc100261d
40. G.Hong, O.Chappey, E.Niel, J.-M.Scherrmann. Enhanced Cellular Uptake and Transport of Polyclonal Immunoglobulin G and Fab After Their Cationization. J Drug Target [Internet] 2000; 8:67-77. Available from:http://informahealthcare.com/doi/abs/10.3109/10611860008996853; PMID:10852339; http://dx.doi.org/10.3109/10611860008996853
41. H.Wu, D.Pfarr, S.Johnson, Y.Brewah, R.Woods, N.Patel, W.White, J.Young, P.Kiener. Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract. J Mol Biol 2007; 368:652-65; PMID:17362988; http://dx.doi.org/10.1016/j.jmb.2007.02.024
42. H.Wu, D.S.Pfarr, Y.Tang, L.-L.An, N.K.Patel, J.D.Watkins, W.D.Huse, P.A.Kiener, J.F.Young. Ultra-potent antibodies against respiratory syncytial virus:effects of binding kinetics and binding valence on viral neutralization. J Mol Biol [Internet] 2005 [cited 2013Feb13]; 350:126-44. Available from:http://www.ncbi.nlm.nih.gov/pubmed/15907931; PMID:15907931; http://dx.doi.org/10.1016/j.jmb.2005.04.049
43. Y.Chen, J.P.Balthasar. Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn. AAPS J 2012; 14:850-9; PMID:22956476; http://dx.doi.org/10.1208/s12248-012-9395-9
44. T.Igawa, S.Ishii, T.Tachibana, A.Maeda, Y.Higuchi, S.Shimaoka, C.Moriyama, T.Watanabe, R.Takubo, Y.Doi, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol [Internet] 2010; 28:1203-7. Available from:http://www.ncbi.nlm.nih.gov/pubmed/20953198; PMID:20953198; http://dx.doi.org/10.1038/nbt.1691
45. Y.Liu, I.Caffry, J.Wu, S.Geng, T.Jain, T.Sun, F.Reid, Y.Cao, P.Estrep, Y.Yu, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs [Internet] 2013 [cited 2014Jan21]; 6:1-10. Available from:http://is.landesbioscience.com/journals/mabs/toc/volume/6/issue/2/; PMID:24284905; http://dx.doi.org/10.4161/mabs.27431
46. P.Estep, F.Reid, C.Nauman, Y.Liu, T.Sun, J.Sun, Y.Xu. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs 2013; 5:270-8; PMID:23575269; http://dx.doi.org/10.4161/mabs.23049